University System of Maryland

Regeneron Pharmaceuticals, Inc.

Regeneran Pharmaceuticals, Inc.

James A Perry

Alan R Shuldiner

Da-Wei Gong

Cristopher Van Hout

Nehal Gosalia

The present disclosure provides methods of treating patients having decreased bone mineral density, methods of identifying subjects having increased risk of developing decreased bone mineral density, methods of detecting human Zinc And Ring Finger 3 (ZNRF3) variant nucleic acid molecules and variant polypeptides, and ZNRF3 variant nucleic acid molecules and variant polypeptides.

Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors

The present disclosure provides methods of treating subjects having increased lipid levels, methods of identifying subjects having an increased risk of developing an increased lipid level, methods of detecting human Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1) variant nucleic acid molecules and variant polypeptides, and SREBF1 variant nucleic acid molecules and variant polypeptides.

Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitors

The present disclosure provides methods of treating subjects having increased lipid levels and/or increased triglyceride levels, methods of identifying subjects having an increased risk of developing an increased lipid level and/or increased triglyceride level, methods of detecting human Sterol Regulatory Element Binding Protein Cleavage-Activating Protein (SCAP) variant nucleic acid molecules and variant polypeptides, and SCAP variant nucleic acid molecules and variant polypeptides.

Growing community of inventors

Baltimore, MD, United States of America

James A Perry